PriceTargets.com logo

NASDAQ:CFMS - Conformis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.33
  • Forecasted Upside: 159.95 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.90 As of 03/5/2021 01:00 AM ET
▼ -0.02 (-2.18%)
1 month | 3 months | 12 months
Get New Conformis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CFMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CFMS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$2.33
▲ +159.95% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Conformis in the last 3 months. The average price target is $2.33, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 159.95% upside from the last price of $0.90.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Conformis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/12/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2020CowenReiterated RatingOutperform$2.00Medium
i
8/6/2020OppenheimerInitiated CoverageBuy$3.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/24/2020CowenReiterated RatingOutperform$2.00High
i
5/12/2020Canaccord GenuityReiterated RatingBuy$2.00High
i
5/12/2020BTIG ResearchReiterated RatingHoldHigh
i
5/12/2020OppenheimerLower Price TargetOutperform$3.50 ➝ $3.00High
i
3/24/2020Canaccord GenuityReiterated RatingBuy$2.00High
i
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
5/2/2019OppenheimerSet Price TargetBuy$4.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/2/2019BTIG ResearchReiterated RatingBuy$3.00High
i
4/2/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$2.50 ➝ $3.50High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
12/14/2018OppenheimerSet Price TargetBuy$3.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/2/2018CowenReiterated RatingBuy$3.00Medium
i
11/1/2018OppenheimerSet Price TargetBuy$3.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/1/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$3.00 ➝ $2.50High
i
9/18/2018OppenheimerReiterated RatingBuyHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/2/2018OppenheimerSet Price TargetBuy$4.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/2/2018BTIG ResearchReiterated RatingBuy$3.00High
i
7/16/2018SunTrust BanksReiterated RatingBuyHigh
i
5/3/2018OppenheimerSet Price TargetBuy$4.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/3/2018BTIG ResearchReiterated RatingBuy$3.00Low
i
Rating by Ryan Zimmerman at BTIG Research
4/10/2018Canaccord GenuityUpgradeHold ➝ Buy$4.00High
i
3/22/2018OppenheimerReiterated RatingBuyHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/12/2018Canaccord GenuityReiterated RatingHoldMedium
i
2/21/2018CowenInitiated CoverageOutperform$1.39 ➝ $4.00High
i
2/8/2018Canaccord GenuityLower Price TargetHold ➝ Hold$5.00 ➝ $4.00Medium
i
2/8/2018OppenheimerSet Price TargetBuy$4.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
1/10/2018BTIG ResearchReiterated RatingBuy$4.00Low
i
Rating by Ryan Zimmerman at BTIG Research
1/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
i
12/20/2017BTIG ResearchUpgradeNeutral ➝ Buy$4.00High
i
Rating by Ryan Zimmerman at BTIG Research
11/2/2017BTIG ResearchReiterated RatingHoldN/A
i
Rating by Ryan Zimmerman at BTIG Research
8/4/2017Canaccord GenuityLower Price TargetHold$8.00 ➝ $6.00Low
i
Rating by Kyle Rose at Canaccord Genuity
8/4/2017OppenheimerSet Price TargetBuy$6.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/4/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Hold$6.00 ➝ $5.00High
i
7/16/2017BTIG ResearchReiterated RatingHoldLow
i
Rating by Ryan Zimmerman at BTIG Research
6/26/2017BTIG ResearchReiterated RatingHoldN/A
i
Rating by Ryan Zimmerman at BTIG Research
6/20/2017OppenheimerReiterated RatingBuyLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/20/2017BTIG ResearchInitiated CoverageNeutralLow
i
5/16/2017B. RileyReiterated RatingBuy$7.50Low
i
5/11/2017B. RileyReiterated RatingBuy$7.50High
i
5/11/2017Canaccord GenuitySet Price TargetHold$8.00Low
i
Rating by Kyle Rose at Canaccord Genuity
5/10/2017OppenheimerSet Price TargetBuy$9.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/21/2017B. RileyReiterated RatingBuy$7.50N/A
i
Rating by greg chodaczek at B. Riley
2/16/2017B. RileyReiterated RatingBuy$7.50N/A
i
Rating by greg chodaczek at B. Riley
2/16/2017Canaccord GenuityDowngradeBuy ➝ Hold$12.00 ➝ $7.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/23/2017Canaccord GenuitySet Price TargetBuy$12.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
11/9/2016B. RileyReiterated RatingBuy$13.00N/A
i
Rating by greg chodaczek at B. Riley
11/4/2016B. RileyReiterated RatingBuy$13.00N/A
i
Rating by greg chodaczek at B. Riley
11/4/2016JPMorgan Chase & Co.Reiterated RatingHold$11.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
10/24/2016OppenheimerSet Price TargetBuy$13.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/21/2016B. RileyInitiated CoverageBuy$13.00N/A
i
Rating by greg chodaczek at B. Riley
9/19/2016SunTrust BanksInitiated CoverageBuy$14.00N/A
i
9/15/2016B. RileyInitiated CoverageBuy$13.00N/A
i
Rating by G. Chodaczek at B. Riley
8/9/2016JPMorgan Chase & Co.Lower Price TargetNeutral$11.00 ➝ $8.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
8/9/2016OppenheimerBoost Price TargetOutperform$12.00 ➝ $13.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/17/2016OppenheimerReiterated RatingOutperform$18.00 ➝ $12.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/14/2016OppenheimerInitiated CoverageBuyN/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/14/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Kyle Rose at Canaccord Genuity
5/13/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$26.00 ➝ $12.00N/A
i
5/13/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
5/13/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $8.00N/A
i
4/5/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
4/5/2016Canaccord GenuityReiterated RatingBuy$18.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
(Data available from 3/5/2016 forward)
Conformis logo
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia. Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $0.90
$0.80
$0.93

50 Day Range

MA: $1.17
$0.92
$1.40

52 Week Range

Now: $0.90
$0.50
$1.49

Volume

7,007,100 shs

Average Volume

7,592,311 shs

Market Capitalization

$85.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Conformis?

The following Wall Street sell-side analysts have issued research reports on Conformis in the last year: BTIG Research, Canaccord Genuity, Cowen Inc, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for CFMS.

What is the current price target for Conformis?

3 Wall Street analysts have set twelve-month price targets for Conformis in the last year. Their average twelve-month price target is $2.33, suggesting a possible upside of 160.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting CFMS will reach $3.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $2.00 for Conformis in the next year.
View the latest price targets for CFMS.

What is the current consensus analyst rating for Conformis?

Conformis currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CFMS will outperform the market and that investors should add to their positions of Conformis.
View the latest ratings for CFMS.

What other companies compete with Conformis?

Other companies that are similar to Conformis include Invacare, Milestone Scientific, Lakeland Industries, United Health Products, Nutriband, Surgalign, Sanara MedTech, Alpha Pro Tech, ReWalk Robotics, CollPlant Biotechnologies, Myomo, Predictive Oncology, Allied Healthcare Products, Advanced Biomedical Technologies and Bionik Laboratories.

How do I contact Conformis' investor relations team?

Conformis' physical mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier's listed phone number is 781-345-9001 and its investor relations email address is [email protected] The official website for Conformis is www.conformis.com.